Log In
BCIQ
Print this Print this
 

HyperAcute Prostate (NLG-11928)

  Manage Alerts
Collapse Summary General Information
Company NewLink Genetics Corp.
DescriptionAlpha 1,3-galactosyltransferase-expressing allogeneic prostate tumor cell vaccine
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase I
Standard IndicationProstate cancer
Indication DetailsTreat castration-resistant prostate cancer (CRPC)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today